A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients
Sponsor: Nanjing Yoko Biomedical Co., Ltd.
Listed as NCT03650933, this PHASE3 trial focuses on Diffuse Large B-Cell Lymphoma, Unspecified Site and remains ongoing. Sponsored by Nanjing Yoko Biomedical Co., Ltd., it has been updated 7 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Nov 2021 — Mar 2024 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing Yoko Biomedical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .